Compare · BLCT vs SLRX
BLCT vs SLRX
Side-by-side comparison of BlueCity Holdings Limited (BLCT) and Salarius Pharmaceuticals Inc. (SLRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- BLCT operates in Technology, while SLRX operates in Health Care - the two are in different parts of the market.
- BLCT is the larger of the two at $152.3M, about 7.8x SLRX ($19.4M).
- SLRX has more recent analyst coverage (2 ratings vs 0 for BLCT).
- Company
- BlueCity Holdings Limited
- Salarius Pharmaceuticals Inc.
- Price
- $1.54+1.64%
- $0.82+36.55%
- Market cap
- $152.3M
- $19.4M
- 1M return
- -
- -3.57%
- 1Y return
- -
- -92.66%
- Industry
- EDP Services
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 2
BlueCity Holdings Limited
BlueCity Holdings Limited operates a platform for LGBTQ community primarily under BlueCity brand in the People's Republic of China, India, South Korea, Thailand, and Vietnam. It operates Blued, a mobile app that offers various services to LGBTQ community, including live streaming, advertising, membership, merchandise sales, and other services. It also offers online health services. BlueCity Holdings Limited was founded in 2011 and is based in Beijing, China.
Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Latest BLCT
- SEC Form 15-12G filed by BlueCity Holdings Limited
- SEC Form S-8 POS filed by BlueCity Holdings Limited
- SEC Form S-8 POS filed by BlueCity Holdings Limited
- SEC Form SC 13D/A filed by BlueCity Holdings Limited (Amendment)
- SEC Form SC 13E3/A filed by BlueCity Holdings Limited (Amendment)
- SEC Form 6-K filed by BlueCity Holdings Limited
- SEC Form 25-NSE filed by BlueCity Holdings Limited
- SEC Form 6-K filed by BlueCity Holdings Limited
- BlueCity Announces Shareholders' Approval Of Merger Agreement
- SEC Form 6-K filed by BlueCity Holdings Limited
Latest SLRX
- SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Director Hanish Arnold C sold $17 worth of shares (27 units at $0.64), closing all direct ownership in the company (SEC Form 4)
- SEC Form 8-K filed by Salarius Pharmaceuticals Inc.
- SEC Form PRE 14A filed by Salarius Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Salarius Pharmaceuticals Inc.
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting